



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Jannis Stavrianopoulos, et al.

Serial No.: 10/763,104

Filed: January 22, 2004

Title: LABEL TARGET AND LABELING REAGENTS
COMPRISING BACKBONES WITH AT LEAST
TWO CONSECUTIVE PEPTIDE BONDS

Group Art Unit: 1645

Examiner: Not Yet Known

527 Madison Avenue, 9th Floor
New York, New York 10022
July 25, 2005

FILED BY EXPRESS MAIL

Commissioner for Patents

P.O. Box 1450


Alexandria, Virginia 22313-1450

ATTN: Mail Stop Missing Parts

**REPLY TO AUGUST 11, 2004 NOTICE TO COMPLY WITH REQUIREMENTS FOR
PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO
ACID SEQUENCE DISCLOSURES – FILING DATE GRANTED**

Dear Sirs:

This reply is directed to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures – Filing Date Granted ("the Notice") that was mailed on August 11, 2004 in connection with this U.S. Patent Application, Serial No. 10/763,104 (the "'104 application"). A copy of the Notice is attached as Exhibit A.


EXPRESS MAIL CERTIFICATE	
"Express Mail" Label No.: <u>EV655204870US</u>	
Deposit Date: <u>July 25, 2005</u>	
I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington DC 20231.	
 Natalie Bogdanos Reg. No. 51,486	<u>7/25/05</u> Date

Enz-61(D4)

Jannis Stavrianopoulos, et al.

Serial No. 10/763,104

Filed: January 22, 2004



Page 2 (Reply to August 11, 2004 Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures – Filing Date Granted) – July 25, 2005)

In response to the Notice, Applicants, through their attorney, submit:

1. a copy of a concurrently filed Petition Under 37 C.F.R. §1.37(b) to Revive an Unintentionally Abandoned Application, annexed herein without its attachments as Exhibit B; and
2. an Amendment, attached herein as Exhibit C, and its attachment identified as Appendix 1, consisting of an initial paper copy of a Sequence Listing as filed on February 3, 2003 in connection with the parent application to this '104 application, namely, U.S. Patent Application Serial No. 10/096,075, along with a copy of the self-addressed stamped postcard acknowledging receipt by the United States Patent and Trademark Office Mailroom of said Sequence Listing, attached as Appendix 2.

In connection with this Reply and the concurrently submitted Amendment herewith, Applicants, through their attorney, request that the Sequence Listing, including the compliant computer readable form thereof, submitted to the United States Patent Office on February 3, 2003 in connection with the parent application of this '104 application, namely, U.S. Patent Application, Serial No. 10/096,075 (the "'075 application"), be made of record in this '104 application. In accordance with 37 CFR §1.821(e), Applicants state that the Sequence Listing, including the compliant computer readable form thereof already on file in connection with Applicants' '075 application, is identical to the Sequence Listing contained in this '104 application. This '104 application is a divisional of the '075 application.

No fee is believed due in connection with this Reply or the documents submitted herewith other than the fee that is due in connection with the aforementioned Petition Under 37 C.F.R. §1.137(b) To Revive An Unintentionally

ENZ-61(D4)

Jannis Stavrianopoulos, et al.

Serial No. 10/763,104

Filed: January 22, 2004

Page 3 (Reply to August 11, 2004 Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures – Filing Date Granted) – July 25, 2005)

Abandoned Application. If any fee or fees are due, the United States Patent and Trademark Office is hereby authorized to charge the amount of any such fee to Deposit Account 05-1135, or to credit any overpayment thereto.

If helpful in processing this Reply, the undersigned may be contacted by telephone at (212) 583-0100 during business hours.

Respectfully submitted,



Natalie Bogdanos

Registration No. 51,480

Attorney for Applicants

ENZO LIFE SCIENCES, INC.

f/k/a Enzo Diagnostics, Inc.

c/o Enzo Biochem, Inc.

527 Madison Avenue (9th Fl.)

New York, New York 10022

Telephone: (212) 583-0100; Fax: (212) 583-0150

al/USProsecution/Enz-61(D4).ReplyToMissingPts.072505

ENZ-61(D4)



JUL 25 2005

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/763,104	01/22/2004	Jannis G. Stavrianopoulos	Enz-61(D4)

CONFIRMATION NO. 7444

Ronald C. Fedus, Esq.
 Enzo Life Sciences, Inc.
 c/o Enzo Biochem, Inc.
 527 Madison Avenue (9th Floor)
 New York, NY 10022-4304

FORMALITIES LETTER



OC000000013499851

Date Mailed: 08/11/2004

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to: Mail Stop Missing Parts
 Commissioner for Patents
 P.O. Box 1450

Alexandria VA 22313-1450

A handwritten signature in black ink, appearing to read "Ahmed", is written over a horizontal line.

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE